UCB SA (OTCMKTS:UCBJF) Receives Average Rating of “Moderate Buy” from Brokerages

by · The Cerbat Gem

Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company.

A number of research firms have issued reports on UCBJF. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a report on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd.

View Our Latest Analysis on UCB

UCB Price Performance

Shares of OTCMKTS:UCBJF opened at $252.09 on Thursday. UCB has a 1 year low of $225.65 and a 1 year high of $345.39. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average is $267.18 and its two-hundred day moving average is $286.89.

UCB Company Profile

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for severe diseases, particularly in neurology and immunology. The company develops treatments for conditions that can have a significant impact on patients’ daily lives and long-term health.

Its portfolio includes medicines such as Cimzia for certain inflammatory conditions, Bimzelx for plaque psoriasis and other immune-mediated diseases, and Briviact, Fintepla and Nayzilam for epilepsy-related disorders.

Featured Stories